Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

NCT06730542 is registered in ClinicalTrials.gov with Juan P. Alderuccio, MD as lead sponsor.

NCT NCT06730542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06730542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Lead sponsor
Juan P. Alderuccio, MD
Phase
Phase 1
Overall status
Recruiting
Start date
April 17, 2025
Completion date
April 30, 2030
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cns lymphoma